AML treatment in older adults

per Sehgal, Alison, Boyiadzis, Michael
Publicat a Aging (Albany NY) (2015)

Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?

per Boyiadzis, Michael, Whiteside, Theresa L.
Publicat a Expert Rev Mol Diagn (2016)

Response Commentary: Exosomes vs microvesicles in hematological malignancies

per Whiteside, Theresa L., Boyiadzis, Michael
Publicat a Leukemia (2017)

PD-1 Checkpoint Blockade in Acute Myeloid Leukemia

per Sehgal, Alison, Whiteside, Theresa L., Boyiadzis, Michael
Publicat a Expert Opin Biol Ther (2015)

Immunotherapy for acute leukemia

per Boyiadzis, Michael, Whiteside, Theresa L, Pavletic, Steven Z
Publicat a Aging (Albany NY) (2015)

Circulating exosomes carrying an immunosuppressive cargo may interfere with adoptive cell therapies in leukemia

per Boyiadzis, Michael, Hong, Chang-Sook, Whiteside, Theresa L
Publicat a J Immunother Cancer (2015)

Biologically-active exosomes in plasma of AML patients inhibit innate immunity and promote leukemia progression

per Boyiadzis, Michael, Hong, Chang-Sook, Whiteside, Theresa L
Publicat a J Immunother Cancer (2015)

Chemotherapy Promotes Release of Exosomes Which Upregulate Cholesterol Synthesis and Chemoresistance in AML Blasts

per Hong, Chang-Sook, Boyiadzis, Michael, Whiteside, Theresa L.
Publicat a J Clin Haematol (2021)

Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts

per Fenton, Moon, Whiteside, Theresa L., Ferrone, Soldano, Boyiadzis, Michael
Publicat a Oncol Res (2015)

Plasma Exosomes as Markers of Therapeutic Response in Patients with Acute Myeloid Leukemia

per Hong, Chang-Sook, Muller, Laurent, Whiteside, Theresa L., Boyiadzis, Michael
Publicat 2014

Isolation and Characterization of CD34+ Blast-Derived Exosomes in Acute Myeloid Leukemia

per Hong, Chang Sook, Muller, Laurent, Boyiadzis, Michael, Whiteside, Theresa L.
Publicat 2014

Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts

per Mehta, Rohtesh S., Chen, Xiaohua, Antony, Jeyaraj, Boyiadzis, Michael, Szabolcs, Paul
Publicat a J Immunother (2016)

Psychosocial experiences of young adults diagnosed with acute leukemia during hospitalization for treatment

per Albrecht, Tara A., Keim-Malpass, Jessica, Boyiadzis, Michael, Rosenzweig, Margaret
Publicat a J Hosp Palliat Nurs (2019)

Increased small extracellular vesicle secretion after chemotherapy via upregulation of cholesterol metabolism in acute myeloid leukaemia

per Hong, Chang-Sook, Jeong, Emily, Boyiadzis, Michael, Whiteside, Theresa L.
Publicat a J Extracell Vesicles (2020)

Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1

per Szczepanski, Miroslaw J., Szajnik, Marta, Welsh, Ann, Whiteside, Theresa L., Boyiadzis, Michael
Publicat 2011

Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer

per Hong, Chang-Sook, Funk, Sonja, Muller, Laurent, Boyiadzis, Michael, Whiteside, Theresa L.
Publicat a J Extracell Vesicles (2016)

Symptom Management and Psychosocial Needs of Adults with Acute Myeloid Leukemia During Induction Treatment: A Pilot Study

per Albrecht, Tara A., Boyiadzis, Michael, Elswick, R.K., Starkweather, Angela, Rosenzweig, Margaret
Publicat a Cancer Nurs (2017)

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

per Szczepanski, Miroslaw J., Szajnik, Marta, Welsh, Ann, Foon, Kenneth A., Whiteside, Theresa L., Boyiadzis, Michael
Publicat 2009

Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia

per Hong, Chang-Sook, Sharma, Priyanka, Yerneni, Saigopalakrishna S., Simms, Patricia, Jackson, Edwin K., Whiteside, Theresa L., Boyiadzis, Michael
Publicat a Sci Rep (2017)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

per Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., Gulley, James L.
Publicat a J Immunother Cancer (2018)